<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dinoprostone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00917</strong>&#160; (APRD00927)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00917/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00917/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00917.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00917.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00917.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00917.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00917.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00917">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Dinoprostone Prostaglandin E2</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>PGE2</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prostaglandin E2</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cervidil</td><td>Forest Laboratories, Inc.</td></tr><tr><td>Prepidil</td><td>Pfizer</td></tr><tr><td>Propess</td><td>Ferring Pharmaceuticals</td></tr><tr><td>Prostarmon E</td><td>DCPC</td></tr><tr><td>PROSTIN</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Prostin E2</td><td>Pfizer Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/oxytocics">Oxytocics</a></li>
<li><a href="/mesh/prostaglandins">Prostaglandins</a></li></ul></td></tr><tr><th>CAS number</th><td>363-24-6</td></tr><tr><th>Weight</th><td>Average: 352.4651<br>Monoisotopic: 352.224974134</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>32</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>XEYBRNLFEZDVAW-ARSRFYASSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Eicosanoids</td></tr><tr><th>Subclass</th><td>Prostaglandins and related compounds</td></tr><tr><th>Direct parent</th><td>Prostaglandins and related compounds</td></tr><tr><th>Alternative parents</th><td>Keto Fatty Acids; Carbocyclic Fatty Acids; Fatty Alcohols; Unsaturated Fatty Acids; Secondary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>fatty alcohol; cyclic alcohol; secondary alcohol; ketone; polyamine; carboxylic acid derivative; enolate; carboxylic acid; alcohol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.</td></tr><tr><th>Pharmacodynamics</th><td>Dinoprostone is equivalent to prostaglandin E2 (PGE2). It stimulates labor and delivery by stimulating the uterine, and thus terminates pregnancy. Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoprostone is used to terminate pregnancy.</td></tr><tr><th>Mechanism of action</th><td>Dinoprostone administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor, resulting in the evacuation of the products of conception from the uterus. It is believed that dinoprostone exerts its uterine effects via direct myometrial stimulation, but the exact mechanism of action is unkown. Other suggested mechanisms include the regulation of cellular membrane calcium transport and of intracellular concentrations of cyclic 3',5'-adenosine monophosphate. Dinoprostone also appears to produce local cervical effects including softening, effacement, and dilation. The exact mechanism of action for this effect is also unknown, but it has been suggested that this effect may be associated with collagen degradation caused by secretion of the enzyme collagenase as a partial response to locally administered dinoprostone.</td></tr><tr><th>Absorption</th><td>Absorbed at a rate of 0.3 mg per hour over 12 hours while the vaginal system is in place.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>73%, to albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys.</p></td></tr><tr><th>Route of elimination</th><td>The major route of elimination of the products of PGE2 metabolism is the kidneys.</td></tr><tr><th>Half life</th><td>Less than 5 minutes.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 750 mg/kg; Oral, rat: LD<sub>50</sub> = 500 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9815</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8704</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5245</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5554</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9202</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8983</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9064</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8211</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8834</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5292</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9502</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9725</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9387
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9201
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6056
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9631 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9087
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9138
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li>
<li>Controlled therapeutics (scotland) ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.ctscotland.com">Controlled Therapeutics Ltd.</a></li>
<li><a href="http://www.forestpharm.com">Forest Pharmaceuticals</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Gel</td><td>Endocervical (intracervical)</td><td></td></tr><tr><td>Gel</td><td>Intravaginal</td><td></td></tr><tr><td>Insert</td><td>Intravaginal</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1664">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6304">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6305">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6306">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 30</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6307">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 35</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6308">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6309">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 45</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6310">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 50</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6311">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 55</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6312">MS/MS Spectrum LC-ESI-QIT (4000Q TRAP, Applied Biosystems) 60</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/7742">MS/MS Spectrum GC-MS </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1605">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01282">Carbetocin</a></td><td>Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>